Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

NCT05103358 is registered in ClinicalTrials.gov with Aadi Bioscience, Inc. as lead sponsor.

NCT NCT05103358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
Lead sponsor
Aadi Bioscience, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 10, 2022
Completion date
December 23, 2024
Enrollment
128 (actual)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, cancer, cancer metastatic, malignant neoplasm, malignant solid neoplasm, malignant solid tumor, malignant tumor, metastasis, metastatic cancer, metastatic neoplasm, metastatic solid tumor, neoplasm metastasis, neoplasms, solid tumor, tsc, tsc1, tsc2, tumor, tumor, solid, tumors